Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 18/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 17/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 17/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 15/20 | 0.66 |
| ▸ | EGFR | P00533 | 9/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11892329 | 0.90 | EGFR (0.56) | HDAC3HDAC1HDAC2HDAC6HDAC10 | |
| SCHEMBL11195217 | 0.90 | KMT2A (0.56) | HDAC3HDAC1HDAC2HDAC6HDAC10 | |
| SCHEMBL10499445 | 0.88 | KMT2A (0.52) | HDAC3HDAC1HDAC2HDAC6HDAC10 | |
| SCHEMBL11892312 | 0.85 | HDAC1 (0.74) | HDAC3HDAC1HDAC2HDAC6HDAC10 | |
| SCHEMBL10602106 | 0.83 | CNR1 (0.66) | KMT2A | |
| SCHEMBL6871770 | 0.82 | HDAC1 (0.65) | HDAC3HDAC1HDAC2HDAC6HDAC10 | |
| SCHEMBL1822139 | 0.79 | KMT2A (0.59) | EGFRKMT2A | |
| SCHEMBL1577697 | 0.79 | HDAC1 (0.71) | HDAC3HDAC1HDAC2HDAC6HDAC10 | |
| SCHEMBL2678367 | 0.77 | CNR1 (0.74) | KMT2A | |
| SCHEMBL2678363 | 0.77 | CNR1 (0.74) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901337-B2 | Metal complexes having dual histone deacetylase inhibitory and DNA-binding activity | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2014-12-02 | — | — | US | disclosed |
| US-20120190874-A1 | METAL COMPLEXES HAVING DUAL HISTONE DEACETYLASE INHIBITORY AND DNA-BINDING ACTIVITY | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190874-A1 | METAL COMPLEXES HAVING DUAL HISTONE DEACETYLASE INHIBITORY AND DNA-BINDING ACTIVITY | HDAC1, HDAC9, HDAC2 | HDAC3 7/4885HDAC1 1/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.